IGC התחייבויות שוטפות של החברה India Globalization Capital

The IGC Pharma, Inc. (IGC) business of developing dementia medications is insulated from market cycles and inflationary fluctuations. The organization's short-term debt clearly demonstrates current balance sheet transparency, with 0.00 serving as the current value of this metric. Cost optimization is achieved through outsourcing drug synthesis to CDMO plants and the organic development of the neuro-pipeline via collaboration with research clinics.

This indicator aggregates all financial obligations of IGC Pharma, Inc. (IGC) with maturities of up to twelve months, capturing current liquidity and the risk of cash flow gaps. By analyzing the short-term debt trend, investors assess the company's ability to fund the costly development of unique cannabinoid drugs for Alzheimer's therapy without imposing a critical debt burden on the operating budget.